Skip to main content

Phase 2 study shows regimen benefit with dasatinib in Ph+ALL therapy

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Phase 2 study shows regimen benefit with dasatinib in Ph+ALL therapy

User login

Username

Password

Reset your password

Type	Lead	score